Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 191-200

  Rajan, Arun ^a   Carter, Corey A ^a   Berman, Arlene ^a   Cao, Liang ^a   Kelly, Ronan J ^a   Thomas, Anish ^a   Khozin, Sean ^a   Chavez, Ariel Lopez ^a   Bergagnini, Isabella ^b   Scepura, Barbara ^a   Szabo, Eva ^a   Lee, Min Jung ^a   Trepel, Jane B ^a   Browne, Sarah K ^c   Rosen, Lindsey B ^c   Yu, Yunkai ^a   Steinberg, Seth M ^a   Chen, Helen X ^a   Riely, Gregory J ^b   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; BELINOSTAT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CIXUTUMUMAB; ERLOTINIB; GEMCITABINE; OCTREOTIDE; PEMETREXED; PREDNISOLONE;

ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; BODY WEIGHT DISORDER; CANCER GROWTH; CANCER PAIN; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DYSPNEA; EPITHELIUM TUMOR; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; MALE; MOUTH ULCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYOSITIS; NAIL DISEASE; NAUSEA; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RESPIRATORY FAILURE; THROMBOCYTOPENIA; THYMOMA; THYMUS CANCER; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR RECURRENCE; VERY ELDERLY; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; RECEPTOR, IGF TYPE 1; THYMUS NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892991988     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70596-5     Document Type: Article

References (30)

1. Detterbeck FC, Parsons AM Thymic tumors. Ann Thorac Surg 2004, 77:1860-1869.
2. Evoli A, Minicuci GM, Vitaliani R, et al. Paraneoplastic diseases associated with thymoma. J Neurol 2007, 254:756-762.
3. Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
4. Rajan A, Giaccone G Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol 2008, 9:277-287.
5. Pollak M The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012, 12:159-169.
6. Chu YW, Schmitz S, Choudhury B, et al. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008, 112:2836-2846.
7. Zucali PA, Petrini I, Lorenzi E, et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010, 116:4686-4695.
8. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007, 13:5834-5840.
9. McKian KP, Haluska P Cixutumumab. Expert Opin Investig Drugs 2009, 18:1025-1033.
10. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008, 68:8039-8048.
11. Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK Determination of human anticytokine autoantibody profiles using a particle-based approach. J Clin Immunol 2012, 32:238-245.
12. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
13. Mehta CR, Patel NR A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Statist Assoc 1983, 78:427-434.
14. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Proc Am Soc Clin Oncol 2006, 24(suppl). abstr 7079.
15. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010, 21:1168-1172.
16. Loehrer PJ, Wang W, Johnson DH, Aisner SC, Ettinger DS Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 2004, 22:293-299.
17. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. Proc Am Soc Clin Oncol 2008, 26(suppl). abstr 19087.
18. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011, 29:2052-2059.
19. Kawashima Y, Inoue A, Sugawara S, et al. Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 7530.
20. McCaffery I, Tudor Y, Deng H, et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res 2013, 19:4282-4289.
21. Mukohara T, Shimada H, Ogasawara N, et al. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 2009, 282:14-24.
22. Becker MA, Hou X, Harrington SC, et al. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 2012, 18:1808-1817.
23. Goto Y, Sekine I, Tanioka M, et al. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 2012, 30:1548-1556.
24. Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012, 30:1849-1856.
25. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012, 30:256-262.
26. Smith TJ Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?. Pharmacol Rev 2010, 62:199-236.
27. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-6053.
28. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003, 9:377-382.
29. Wang Y, Lipari P, Wang X, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 2010, 9:410-418.
30. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009, 69:7662-7671.